SCHEMBL1121599

SCHEMBL1121599

Fc1sc2ccccc2c1CBr

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.44
CYP2D6 P10635 2/20 0.37
CHRM1 P11229 1/20 0.37
HTR2A P28223 1/20 0.37
HRH1 P35367 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
CYP2A6 P11509 2/20 0.34
ALDH1A1 P00352 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 3/20 0.33
RAB9A P51151 3/20 0.33
CYP1A2 P05177 2/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
HSD17B10 Q99714 1/20 0.33
FTO Q9C0B1 1/20 0.33
IDO1 P14902 1/20 0.33
MCL1 Q07820 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22263115 0.78 GPR3 (0.46) GPR3CYP2D6CHRM1HTR2AHRH1
SCHEMBL23132153 0.78 GPR3 (0.46) GPR3CYP2D6CHRM1HTR2AHRH1
SCHEMBL31499102 0.78 GPR3 (0.46) GPR3CYP2D6CHRM1HTR2AHRH1
SCHEMBL10364177 0.76 GPR3 (0.44) GPR3CYP2D6LOXL2ALDH1A1MAPT
SCHEMBL9394591 0.73 CNR2 (0.43) GPR3CYP2D6CHRM1HTR2AHRH1
SCHEMBL11531429 0.73 L3MBTL1 (0.42) GPR3LOXL2ALDH1A1L3MBTL1MAPT
SCHEMBL30313373 0.72 GPR3 (0.55) GPR3LOXL2CYP2A6ALDH1A1L3MBTL1
SCHEMBL3480809 0.72 GPR3 (0.55) GPR3LOXL2CYP2A6ALDH1A1L3MBTL1
SCHEMBL9393951 0.71 MCL1 (0.58) CYP1A2MCL1LMNA
SCHEMBL7987786 0.69 MAPT (0.45) ALDH1A1MAPTRAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 EP disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A GPR3 156/4885CYP2D6 532/4885CHRM1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.